Logo image of SRRK

SCHOLAR ROCK HOLDING CORP (SRRK) Stock Price, Quote, News and Overview

NASDAQ:SRRK - Nasdaq - US80706P1030 - Common Stock - Currency: USD

39.15  +1.14 (+3%)

After market: 39.15 0 (0%)

SRRK Quote, Performance and Key Statistics

SCHOLAR ROCK HOLDING CORP

NASDAQ:SRRK (2/20/2025, 5:20:00 PM)

After market: 39.15 0 (0%)

39.15

+1.14 (+3%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High46.98
52 Week Low6.76
Market Cap3.66B
Shares93.61M
Float91.75M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)02-27 2025-02-27/amc
IPO05-24 2018-05-24


SRRK short term performance overview.The bars show the price performance of SRRK in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 100 200 300

SRRK long term performance overview.The bars show the price performance of SRRK in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300

The current stock price of SRRK is 39.15 USD. In the past month the price decreased by -16.22%. In the past year, price increased by 150.96%.

SCHOLAR ROCK HOLDING CORP / SRRK Daily stock chart

SRRK Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.85 354.98B
AMGN AMGEN INC 15.03 159.99B
GILD GILEAD SCIENCES INC 23.87 137.10B
VRTX VERTEX PHARMACEUTICALS INC 1656.31 123.40B
REGN REGENERON PHARMACEUTICALS 15.25 76.09B
ARGX ARGENX SE - ADR N/A 39.34B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.37B
BNTX BIONTECH SE-ADR N/A 28.26B
ONC BEIGENE LTD-ADR N/A 26.06B
NTRA NATERA INC N/A 22.20B
BIIB BIOGEN INC 8.32 19.98B
SMMT SUMMIT THERAPEUTICS INC N/A 17.01B

About SRRK

Company Profile

SRRK logo image Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 150 full-time employees. The company went IPO on 2018-05-24. The firm is focused on the discovery, development and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled the Company to develop a proprietary platform for the development of monoclonal antibodies that locally and selectively target the precursor. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as the first muscle-targeted therapy for the treatment of spinal muscular atrophy (SMA). Its other product candidate, SRK-181, a selective inhibitor of the activation of latent TGFb, is being developed for the treatment of cancers.

Company Info

SCHOLAR ROCK HOLDING CORP

301 Binney Street, 3rd Floor

Cambridge MASSACHUSETTS 02142 US

CEO: Stuart A. Kingsley

Employees: 150

Company Website: https://scholarrock.com/

Investor Relations: https://investors.scholarrock.com/

Phone: 18572593860

SCHOLAR ROCK HOLDING CORP / SRRK FAQ

What is the stock price of SCHOLAR ROCK HOLDING CORP today?

The current stock price of SRRK is 39.15 USD. The price increased by 3% in the last trading session.


What is the ticker symbol for SCHOLAR ROCK HOLDING CORP stock?

The exchange symbol of SCHOLAR ROCK HOLDING CORP is SRRK and it is listed on the Nasdaq exchange.


On which exchange is SRRK stock listed?

SRRK stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for SCHOLAR ROCK HOLDING CORP stock?

15 analysts have analysed SRRK and the average price target is 46.63 USD. This implies a price increase of 19.1% is expected in the next year compared to the current price of 39.15. Check the SCHOLAR ROCK HOLDING CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is SCHOLAR ROCK HOLDING CORP worth?

SCHOLAR ROCK HOLDING CORP (SRRK) has a market capitalization of 3.66B USD. This makes SRRK a Mid Cap stock.


How many employees does SCHOLAR ROCK HOLDING CORP have?

SCHOLAR ROCK HOLDING CORP (SRRK) currently has 150 employees.


What are the support and resistance levels for SCHOLAR ROCK HOLDING CORP (SRRK) stock?

SCHOLAR ROCK HOLDING CORP (SRRK) has a support level at 37.06 and a resistance level at 45.48. Check the full technical report for a detailed analysis of SRRK support and resistance levels.


Should I buy SCHOLAR ROCK HOLDING CORP (SRRK) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does SCHOLAR ROCK HOLDING CORP (SRRK) stock pay dividends?

SRRK does not pay a dividend.


When does SCHOLAR ROCK HOLDING CORP (SRRK) report earnings?

SCHOLAR ROCK HOLDING CORP (SRRK) will report earnings on 2025-02-27, after the market close.


What is the Price/Earnings (PE) ratio of SCHOLAR ROCK HOLDING CORP (SRRK)?

SCHOLAR ROCK HOLDING CORP (SRRK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.35).


What is the Short Interest ratio of SCHOLAR ROCK HOLDING CORP (SRRK) stock?

The outstanding short interest for SCHOLAR ROCK HOLDING CORP (SRRK) is 17% of its float. Check the ownership tab for more information on the SRRK short interest.


SRRK Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to SRRK. When comparing the yearly performance of all stocks, SRRK is one of the better performing stocks in the market, outperforming 96.81% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

SRRK Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to SRRK. While SRRK seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SRRK Financial Highlights

Over the last trailing twelve months SRRK reported a non-GAAP Earnings per Share(EPS) of -2.35. The EPS decreased by -20.51% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -89.85%
ROE -152.56%
Debt/Equity 0.37
Chartmill High Growth Momentum
EPS Q2Q%-24.53%
Sales Q2Q%N/A
EPS 1Y (TTM)-20.51%
Revenue 1Y (TTM)-100%

SRRK Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to SRRK. The Buy consensus is the average rating of analysts ratings from 15 analysts.


Ownership
Inst Owners98.98%
Ins Owners1.12%
Short Float %17%
Short Ratio16.54
Analysts
Analysts85.33
Price Target46.63 (19.11%)
EPS Next Y-24.51%
Revenue Next YearN/A